SAMARIUM SM-153 LEXIDRONAM PENTASODIUM bulk active fine chemical vendors

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
MuseChem	⤷ Get Started Free	M134746	⤷ Get Started Free
THE BioTek	⤷ Get Started Free	bt-1216345	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: November 18, 2025

Introduction

Samarium Sm-153 lexidronam pentasodium, commercially known as Quadramet, is a targeted radiopharmaceutical used predominantly for palliative treatment of pain in patients with osteoblastic metastatic bone lesions. Its unique mechanism involves delivering localized beta radiation to bone metastases, thus alleviating pain with minimal systemic exposure. Given its specialized application and the intricate process of manufacturing a radionuclide-based API, identifying reliable bulk sources is critical for pharmaceutical companies, regulatory compliance, and healthcare providers.

This report delineates the current landscape of bulk API sources for Samarium Sm-153 lexidronam pentasodium, emphasizing manufacturing origins, regulatory status, supply chain considerations, and emerging production capabilities.

Overview of Samarium Sm-153 Lexidronam Pentasodium

Chemical and Radiopharmaceutical Profile

Samarium Sm-153 is a beta-emitting radioisotope with a half-life of approximately 1.9 days, facilitating rapid decay post-administration, reducing long-term radiation exposure. When chelated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylene)phosphonic acid (also known as EDDA), it forms Sm-153 lexidronam pentasodium, which exhibits high affinity for bone mineral matrices.

Manufacturing Challenges

The production involves complex steps: isotope procurement, chelation process, formulation under stringent GMP conditions, and rigorous quality assurance. As a result, sourcing bulk APIs demands access to specialized facilities capable of handling radioactive materials safely.

Key Suppliers of Bulk API for Samarium Sm-153 Lexidronam Pentasodium

1. Radioisotope Production Facilities

The foundation of supply lies in the availability of the radioisotope samarium-153:

Eckert & Ziegler Isotope Products
A prominent supplier offering high-purity samarium-153 oxide and chloride. They provide radiochemically pure sources suitable for pharmaceutical manufacturing. With ISO and GMP certifications, their products are increasingly integrated into licensed radiopharmacies globally.
MDS Nordion (Canada)
Historically one of the largest producers of medical isotopes, MDS Nordion supplied samarium-153 for research and clinical applications. Though the company divested some operations, its legacy products and licensing agreements continue to influence the supply chain.
Institute for Transuranium Elements (JRC-ITU) – European Union
The JRC-ITU in Karlsruhe, Germany, produces low-activity samarium-153 for research purposes, with certain collaborations enabling scaled production for medical use under strict regulatory oversight.
Nordion (part of Nordion, now part of Cerba Industrial & Scientific Services)
Continues to produce and supply samarium isotopes, integrating them into pharmaceutical-grade platforms for radiopharmaceutical development.

2. Pharmaceutical and Radiopharmaceutical Manufacturers

Large-scale production of Sm-153 lexidronam involves not only obtaining the isotope but also executing the complex chelation and formulation steps:

Nordion (Canada)
Historically supplied the complete product, including the finished radiopharmaceutical. Their facilities comply with Good Manufacturing Practice (GMP), ensuring quality and regulatory acceptance in multiple markets.
Pharmacyclics (AbbVie/ formerly)
A key player involved in formulation and commercialization of radiopharmaceuticals, including contribution from specialized contract manufacturing organizations (CMOs) for API synthesis.
Indigenous and Regional Providers
Several Asia-Pacific facilities, particularly in India and China, have developed capabilities for producing samarium-based radiopharmaceuticals. Examples include:
- Bhabha Atomic Research Centre (BARC), India
  Produces a variety of radioisotopes, including samarium-153, mainly for research, but scaled-up production aligns with pharmaceutical-grade needs.
- Chinese Academy of Sciences
  Engaged in isotope production with some facilities capable of generating clinical-grade samarium radionuclides.

3. Contract Manufacturing Organizations (CMOs)

Several CMOs globally offer custom synthesis, including radionuclide chelation, especially in the context of radiopharmaceutical development:

Excellent Advanced Technology (Canada)
Specializes in radionuclide production and radiopharmaceutical manufacturing, including API synthesis with compliance to GMP standards.
5D Medical (United States)
Focused on personalized radiopharmaceuticals with flexible production capacity for isotope formulation.
Mallinckrodt Pharmaceuticals
Historically contributed to the supply chain with radiochemical formulations; their current capabilities depend on strategic reorganization.

Supply Chain Considerations and Regulatory Aspects

The supply of samarium Sm-153 lexidronam API hinges on the availability of its radionuclide precursor, adherence to GMP, and strict regulatory oversight, particularly from agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and corresponding regional authorities. These agencies impose rigorous standards on production facilities, including licensing, quality testing, and traceability.

Because of its radioactive nature, transportation and storage of the API are subjected to strict safety protocols, often limiting the number of qualified suppliers capable of providing consistent, high-purity bulk APIs.

Emerging Capabilities and Industry Trends

Recent investments in regional nuclear medicine infrastructure aim to decentralize isotope production, reducing reliance on aging facilities and supply disruptions:

Cyclotron-based Production
Development of cyclotron methods for direct production of samarium-153 reduces dependence on nuclear reactors and allows local, on-demand manufacturing, improving supply stability.
Generator Technologies
Innovations in generator systems may facilitate on-site preparation of the isotope, offering greater flexibility for hospitals and radiopharmacies.
Regulatory Harmonization and Supply Security
Cross-border collaborations, licensing mutual recognition, and streamlined approval pathways enhance availability of bulk APIs globally.

Conclusion

The bulk API landscape for Samarium Sm-153 lexidronam pentasodium is characterized by a limited but highly specialized network of suppliers capable of producing high-purity radionuclides and formulating the final API under strict regulatory conditions. Major players such as Eckert & Ziegler, MDS Nordion, and regional manufacturers like BARC and Chinese energy institutes are at the forefront. Strategic investments in local production capabilities, coupled with technological advancements, promise to enhance supply security, especially amid geopolitical and pandemic-induced disruptions.

Key Takeaways

Limited but Critical Supply Chain: The production of Samarium Sm-153 lexidronam API relies on specialized facilities capable of handling radioactive isotopes, making the supply chain narrow and strategic.
Regulatory Compliance is Paramount: Suppliers must have GMP certifications and robust quality assurance processes aligning with regional and international regulations.
Emerging Technologies Enhance Supply Stability: Cyclotron production and generator-based methods are developing to mitigate dependence on reactor-based isotopes.
Regional Production is Growing: Countries like India and China are increasingly capable of producing GMP-grade samarium isotopes, expanding the global supply network.
Business and Clinical Implications: Reliable sourcing directly influences availability, pricing, and adoption of Samarium Sm-153 based therapies, impacting healthcare outcomes and commercial viability.

FAQs

1. Who are the primary global suppliers of bulk samarium-153 for pharmaceutical use?
Major suppliers include Eckert & Ziegler, MDS Nordion, and specialized regional facilities such as BARC in India and Chinese research institutes, all capable of providing high-purity samarium-153 suitable for radiopharmaceutical manufacturing.

2. What regulatory standards govern the bulk production of Samarium Sm-153 lexidronam API?
Standards set by agencies like the FDA, EMA, and regional nuclear regulatory bodies require GMP compliance, rigorous quality control, accurate radionuclide characterization, and safe handling protocols.

3. How is supply chain resilience improving for Samarium Sm-153?
Advances in cyclotron-based production, local regional facilities, and generator technologies are reducing dependence on aging reactor-based isotope production, enhancing supply stability.

4. What challenges exist in sourcing bulk Samarium Sm-153 for commercial radiopharmaceutical manufacturing?
Key challenges include limited producer capacity, stringent regulatory requirements, high costs of handling radioactive materials, and geopolitical factors affecting isotope availability.

5. Are there alternative isotopes or radiopharmaceuticals for pain palliation in osteoblastic metastases?
Yes, alternatives like Radium-223 dichloride (Xofigo) and Strontium-89 are used, but each has distinct pharmacokinetics and efficacy profiles, making Samarium-153 lexidronam unique in its clinical niche.

Sources:
[1] Eckert & Ziegler. "Medical Isotopes and Radiopharmaceuticals." Accessed 2023.
[2] MDS Nordion. "Radioisotope Production Capabilities." Corporate disclosures, 2022.
[3] Bhabha Atomic Research Centre. "Radionuclide Production Facilities." Official reports, 2021.
[4] European Commission. "Regulation of Radioactive Pharmaceuticals." 2022.
[5] World Nuclear Association. "Nuclear Medicine and Radionuclide Supply." 2022.

Bulk Pharmaceutical API Sources for samarium sm-153 lexidronam pentasodium